VIR 576

Drug Profile

VIR 576

Alternative Names: VIR-576; VIR-576 anchoring inhibitor - VIRO Pharmaceuticals GmbH

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VIRO Pharmaceuticals
  • Class Antiretrovirals
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 11 May 2010 Phase-I/II clinical trials in HIV infections in Germany (IV infusion)
  • 11 May 2010 Efficacy & adverse events data from a phase I/II trial in HIV infections presented at the 12th European AIDS conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top